Q1 Earnings Forecast for ALDX Issued By HC Wainwright

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Equities researchers at HC Wainwright issued their Q1 2025 earnings estimates for shares of Aldeyra Therapeutics in a report issued on Monday, March 3rd. HC Wainwright analyst M. Caufield forecasts that the biotechnology company will post earnings per share of ($0.25) for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.20) EPS, Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at $0.08 EPS, FY2028 earnings at $0.48 EPS and FY2029 earnings at $1.00 EPS.

Aldeyra Therapeutics Stock Down 0.3 %

Shares of NASDAQ:ALDX opened at $6.15 on Thursday. The company’s 50-day moving average price is $5.53 and its 200 day moving average price is $5.40. Aldeyra Therapeutics has a fifty-two week low of $2.71 and a fifty-two week high of $6.92. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.30).

Institutional Trading of Aldeyra Therapeutics

Several hedge funds have recently bought and sold shares of the company. US Bancorp DE acquired a new position in Aldeyra Therapeutics during the 3rd quarter valued at about $30,000. Hsbc Holdings PLC acquired a new position in Aldeyra Therapeutics during the 4th quarter valued at about $52,000. Balyasny Asset Management L.P. acquired a new position in Aldeyra Therapeutics during the 4th quarter valued at about $56,000. Paloma Partners Management Co acquired a new position in Aldeyra Therapeutics during the 3rd quarter valued at about $62,000. Finally, Catalyst Funds Management Pty Ltd increased its stake in Aldeyra Therapeutics by 2,083.3% during the 4th quarter. Catalyst Funds Management Pty Ltd now owns 13,100 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 12,500 shares during the period. 59.71% of the stock is currently owned by institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.